Safety and tolerability of AZD8055 in Japanese patients with advanced solid tumors; a dose-finding phase I study

Abstract A168: First results from a phase I trial of AZD8055, a dual mTORC1 and mTORC2 inhibitor.

(2012) A. Naing et al.   MOLECULAR CANCER THERAPEUTICS

A Phase I, dose-finding and pharmacokinetic study of olaparib (AZD2281) in Japanese patients with advanced solid tumors*,†

(2011) Noboru Yamamoto et al.   CANCER SCIENCE

Approaches to Japanese Dose Evaluation in Global Drug Development: Factors That Generate Different Dosages Between Japan and the United States

(2011) K Nakashima et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Pushing the Envelope in the mTOR Pathway: The Second Generation of Inhibitors

(2011) E. Vilar et al.   MOLECULAR CANCER THERAPEUTICS

Rapamycin passes the torch: a new generation of mTOR inhibitors

(2011) Don Benjamin et al.   NATURE REVIEWS DRUG DISCOVERY

Mechanisms of mTOR inhibitor resistance in cancer therapy

(2011) Jennifer S. Carew et al.   Targeted Oncology

AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with In vitro and In vivo Antitumor Activity

(2009) C. M. Chresta et al.   CANCER RESEARCH

Ethnic differences in drug metabolism and toxicity from chemotherapy

(2009) Viet Hong Phan et al.   Expert Opinion on Drug Metabolism & Toxicology